Fig. 3
From: Human fetal lung mesenchymal stem cells ameliorate lung injury in an animal model
Bronchoalveolar lavage fluid NO levels and lung edema assessment. (A) BALF NO concentration: Levels of nitric oxide were measured in bronchoalveolar lavage fluid on days 3, 7, 14, and 28 after acute lung injury and cell therapy with hFL-MSCs. The + BLM group shows significant increases compared to controls (− BLM) at various time points, which are significantly reduced in the BLM + MSC group. (B) Lung wet/dry weight ratio. To evaluate the extent of lung edema, this index was determined on days 3, 7, 14, and 28 after acute lung injury and cell therapy with hFL-MSCs. The + BLM group shows significant accumulation of fluid compared to controls (− BLM) up to day 7. In BLM + MSC group, cell therapy prevented significant fluid accumulation up to day 14. Abbreviations: BALF, bronchoalveolar lavage fluid; NO, nitric oxide; −BLM, the control rats received PBS instead of bleomycin and cell suspension; +BLM, the rats sustained induced ALI with bleomycin that did not undergo cell therapy, received PBS instead of cell suspension; BLM + MSC, the rats sustained ALI with bleomycin that underwent cell therapy with human fetal lung mesenchymal cells at day 0; W/D ratio, wet/dry weight ratio. Data are mean ± SD; *p < 0.05, **p < 0.01, ***p < 0.001 (Only statistically significant differences between groups are indicated in the figure).
